Key Facts
| Industry | Pharmaceutical Contract Developer and Contract Manufacturer (CDMO) |
| Business Model | Development and production of pharmaceutical products on behalf of customers , as well as the development, production and sales of own products. |
| Turnover | ca. 20 million euros p/a |
| Staff complement | 140 |
| Acquisition date | October 2013 |
| Fund advised by DUBAG | Lenbach Equity Opportunities I. SCSp |
| Exit | The company was divested to Daicel corporation in August 2018 |
Operational Details
Initial and/or special situation
- Non-core subsidiary former shareholder, a medium-sized business group
- High debt level of debt, commitment of the banks was failing
- Declining, low turnover due to the absence of a sales force
- General lack of structures / functions in the company
- High single-customer concentration
Turnaround results
- Successful implementation of a sales department
- Missing structures were created and new positions were filled
- Expansion of the existing customer base
- Significant reduction of financial liabilities
- Reintroduction of “own” products
- Significant increase in sales and earnings
